Literature DB >> 17684613

Radioiodine therapy and subsequent pregnancy.

Carmen Dolores G Brandão1, Angélica E Miranda, Nilson Duarte Corrêa, Lino Sieiro Netto, Rossana Corbo, Mario Vaisman.   

Abstract

OBJECTIVES: To evaluate abortion and fetal congenital anomaly rates in women previously submitted to radioiodine therapy for differentiated thyroid carcinoma. STUDY
DESIGN: A case-control study of 108 pregnant women, 48 cases whose pregnancies were evaluated after they had undergone radioiodine therapy for differentiated thyroid carcinoma, and the control group consisted of 60 healthy pregnant women.
RESULTS: Of a total of 66 pregnancies, 14 conceived within the first year, 51 one or more years after the last administration of 131I, the medical record of one patient was not available. The interval between the last radioiodine therapy administration and conception ranged from 1 month to 10 years. There were a total of 4 miscarriages, 2 of them for unknown reasons. There was one case of congenital anomaly and two preterms birth. Nine women presented the following pregnancy events: placental insufficiency, hypertensive crisis, placental detachment, risk of miscarriage, preterm labour and four miscarriages. No statistical difference was observed between the studied and control groups.
CONCLUSION: Radioiodine was followed by no significant increase in untoward effects in neither the pregnancy nor the offspring.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684613     DOI: 10.1590/s0004-27302007000400006

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  2 in total

Review 1.  Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Shinje Moon; Ka Hee Yi; Young Joo Park
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

2.  Pregnancy Outcome After I-131 Therapy for Patients With Thyroid Cancer: A Nationwide Population-Based Cohort Study.

Authors:  Kuan-Yin Ko; Ruoh-Fang Yen; Cheng-Li Lin; Mei-Fang Cheng; Wen-Sheng Huang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.